Puma says cancer drug meets trial goal, shares soar

July 22, 2014 10:06 PM

16 0

Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.

Puma said on Tuesday it plans to file for marketing approval of neratinib, code named PB272, in the first half of 2015.

Read more

To category page